Skip to content

Abbott Laboratories

NYSE: ABT · USD

Abbott Laboratories financials

6 charts

Revenue

USD millions

$12,593M
Abbott Laboratories Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$7,494.876M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$7,761.336M; +3.6% vs FY 2009 Q2
FY 2009 Q4$8,790.1M; +13.3% vs FY 2009 Q3
FY 2010 Q1$7,698.354M; −12.4% vs FY 2009 Q4
FY 2010 Q2$8,826.014M; +14.6% vs FY 2010 Q1
FY 2010 Q3$8,674.505M; −1.7% vs FY 2010 Q2
FY 2010 Q4$9,967.8M; +14.9% vs FY 2010 Q3
FY 2011 Q1$9,040.85M; −9.3% vs FY 2010 Q4
FY 2011 Q2$9,616.291M; +6.4% vs FY 2011 Q1
FY 2011 Q3$9,816.665M; +2.1% vs FY 2011 Q2
FY 2011 Q4$10,377.4M; +5.7% vs FY 2011 Q3
FY 2012 Q1$9,456.633M; −8.9% vs FY 2011 Q4
FY 2012 Q2$9,807.1M; +3.7% vs FY 2012 Q1
FY 2012 Q3$9,773.241M; −0.3% vs FY 2012 Q2
FY 2012 Q4$10,836.9M; +10.9% vs FY 2012 Q3
FY 2013 Q1$5,377.895M; −50.4% vs FY 2012 Q4
FY 2013 Q2$5,446.025M; +1.3% vs FY 2013 Q1
FY 2013 Q3$5,369.138M; −1.4% vs FY 2013 Q2
FY 2013 Q4$5,655M; +5.3% vs FY 2013 Q3
FY 2014 Q1$5,244M; −7.3% vs FY 2013 Q4
FY 2014 Q2$5,551M; +5.9% vs FY 2014 Q1
FY 2014 Q3$5,104M; −8.1% vs FY 2014 Q2
FY 2014 Q4$5,356M; +4.9% vs FY 2014 Q3
FY 2015 Q1$4,897M; −8.6% vs FY 2014 Q4
FY 2015 Q2$5,170M; +5.6% vs FY 2015 Q1
FY 2015 Q3$5,150M; −0.4% vs FY 2015 Q2
FY 2015 Q4$5,188M; +0.7% vs FY 2015 Q3
FY 2016 Q1$4,885M; −5.8% vs FY 2015 Q4
FY 2016 Q2$5,333M; +9.2% vs FY 2016 Q1
FY 2016 Q3$5,302M; −0.6% vs FY 2016 Q2
FY 2016 Q4$5,333M; +0.6% vs FY 2016 Q3
FY 2017 Q1$6,335M; +18.8% vs FY 2016 Q4
FY 2017 Q2$6,637M; +4.8% vs FY 2017 Q1
FY 2017 Q3$6,829M; +2.9% vs FY 2017 Q2
FY 2017 Q4$7,589M; +11.1% vs FY 2017 Q3
FY 2018 Q1$7,390M; −2.6% vs FY 2017 Q4
FY 2018 Q2$7,767M; +5.1% vs FY 2018 Q1
FY 2018 Q3$7,656M; −1.4% vs FY 2018 Q2
FY 2018 Q4$7,765M; +1.4% vs FY 2018 Q3
FY 2019 Q1$7,535M; −3.0% vs FY 2018 Q4
FY 2019 Q2$7,979M; +5.9% vs FY 2019 Q1
FY 2019 Q3$8,076M; +1.2% vs FY 2019 Q2
FY 2019 Q4$8,314M; +2.9% vs FY 2019 Q3
FY 2020 Q1$7,726M; −7.1% vs FY 2019 Q4
FY 2020 Q2$7,328M; −5.2% vs FY 2020 Q1
FY 2020 Q3$8,853M; +20.8% vs FY 2020 Q2
FY 2020 Q4$10,701M; +20.9% vs FY 2020 Q3
FY 2021 Q1$10,456M; −2.3% vs FY 2020 Q4
FY 2021 Q2$10,223M; −2.2% vs FY 2021 Q1
FY 2021 Q3$10,928M; +6.9% vs FY 2021 Q2
FY 2021 Q4$11,468M; +4.9% vs FY 2021 Q3
FY 2022 Q1$11,895M; +3.7% vs FY 2021 Q4
FY 2022 Q2$11,257M; −5.4% vs FY 2022 Q1
FY 2022 Q3$10,410M; −7.5% vs FY 2022 Q2
FY 2022 Q4$10,091M; −3.1% vs FY 2022 Q3
FY 2023 Q1$9,747M; −3.4% vs FY 2022 Q4
FY 2023 Q2$9,978M; +2.4% vs FY 2023 Q1
FY 2023 Q3$10,143M; +1.7% vs FY 2023 Q2
FY 2023 Q4$10,241M; +1.0% vs FY 2023 Q3
FY 2024 Q1$9,964M; −2.7% vs FY 2023 Q4
FY 2024 Q2$10,377M; +4.1% vs FY 2024 Q1
FY 2024 Q3$10,635M; +2.5% vs FY 2024 Q2
FY 2024 Q4$10,974M; +3.2% vs FY 2024 Q3
FY 2025 Q1$10,358M; −5.6% vs FY 2024 Q4
FY 2025 Q2$11,142M; +7.6% vs FY 2025 Q1
FY 2025 Q3$11,369M; +2.0% vs FY 2025 Q2
FY 2025 Q4$11,459M; +0.8% vs FY 2025 Q3
FY 2026 Q1$11,164M; −2.6% vs FY 2025 Q4
FY 2026 Q2$12,593M; +12.8% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

$1,991M
Abbott Laboratories Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$1,451.061M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$2,701.314M; +86.2% vs FY 2009 Q2
FY 2009 Q4Unavailable; Change unavailable vs FY 2009 Q3
FY 2010 Q1$1,277.609M; Change unavailable vs FY 2009 Q4
FY 2010 Q2$2,074.783M; +62.4% vs FY 2010 Q1
FY 2010 Q3$2,343.328M; +12.9% vs FY 2010 Q2
FY 2010 Q4$2,025.186M; −13.6% vs FY 2010 Q3
FY 2011 Q1$1,619.333M; −20.0% vs FY 2010 Q4
FY 2011 Q2$2,130.195M; +31.5% vs FY 2011 Q1
FY 2011 Q3$2,602.435M; +22.2% vs FY 2011 Q2
FY 2011 Q4$1,126.614M; −56.7% vs FY 2011 Q3
FY 2012 Q1$1,771.6M; +57.2% vs FY 2011 Q4
FY 2012 Q2$1,641.713M; −7.3% vs FY 2012 Q1
FY 2012 Q3$2,988.755M; +82.1% vs FY 2012 Q2
FY 2012 Q4$1,117.044M; −62.6% vs FY 2012 Q3
FY 2013 Q1$185.79M; −83.4% vs FY 2012 Q4
FY 2013 Q2$426.14M; +129.4% vs FY 2013 Q1
FY 2013 Q3$245.668M; −42.4% vs FY 2013 Q2
FY 2013 Q4$1,321.402M; +437.9% vs FY 2013 Q3
FY 2014 Q1$81M; −93.9% vs FY 2013 Q4
FY 2014 Q2$642M; +692.6% vs FY 2014 Q1
FY 2014 Q3$924M; +43.9% vs FY 2014 Q2
FY 2014 Q4$951M; +2.9% vs FY 2014 Q3
FY 2015 Q1$-233M; −124.5% vs FY 2014 Q4
FY 2015 Q2$725M; +411.2% vs FY 2015 Q1
FY 2015 Q3$784M; +8.1% vs FY 2015 Q2
FY 2015 Q4$580M; −26.0% vs FY 2015 Q3
FY 2016 Q1$-336M; −157.9% vs FY 2015 Q4
FY 2016 Q2$662M; +297.0% vs FY 2016 Q1
FY 2016 Q3$905M; +36.7% vs FY 2016 Q2
FY 2016 Q4$851M; −6.0% vs FY 2016 Q3
FY 2017 Q1$302M; −64.5% vs FY 2016 Q4
FY 2017 Q2$1,096M; +262.9% vs FY 2017 Q1
FY 2017 Q3$1,742M; +58.9% vs FY 2017 Q2
FY 2017 Q4$1,295M; −25.7% vs FY 2017 Q3
FY 2018 Q1$833M; −35.7% vs FY 2017 Q4
FY 2018 Q2$946M; +13.6% vs FY 2018 Q1
FY 2018 Q3$1,829M; +93.3% vs FY 2018 Q2
FY 2018 Q4$1,298M; −29.0% vs FY 2018 Q3
FY 2019 Q1$377M; −71.0% vs FY 2018 Q4
FY 2019 Q2$592M; +57.0% vs FY 2019 Q1
FY 2019 Q3$1,547M; +161.3% vs FY 2019 Q2
FY 2019 Q4$1,982M; +28.1% vs FY 2019 Q3
FY 2020 Q1$355M; −82.1% vs FY 2019 Q4
FY 2020 Q2$680M; +91.5% vs FY 2020 Q1
FY 2020 Q3$1,570M; +130.9% vs FY 2020 Q2
FY 2020 Q4$3,119M; +98.7% vs FY 2020 Q3
FY 2021 Q1$2,240M; −28.2% vs FY 2020 Q4
FY 2021 Q2$1,715M; −23.4% vs FY 2021 Q1
FY 2021 Q3$2,240M; +30.6% vs FY 2021 Q2
FY 2021 Q4$2,453M; +9.5% vs FY 2021 Q3
FY 2022 Q1$1,744M; −28.9% vs FY 2021 Q4
FY 2022 Q2$2,031M; +16.5% vs FY 2022 Q1
FY 2022 Q3$2,313M; +13.9% vs FY 2022 Q2
FY 2022 Q4$1,716M; −25.8% vs FY 2022 Q3
FY 2023 Q1$763M; −55.5% vs FY 2022 Q4
FY 2023 Q2$696M; −8.8% vs FY 2023 Q1
FY 2023 Q3$1,317M; +89.2% vs FY 2023 Q2
FY 2023 Q4$2,283M; +73.3% vs FY 2023 Q3
FY 2024 Q1$627M; −72.5% vs FY 2023 Q4
FY 2024 Q2$1,427M; +127.6% vs FY 2024 Q1
FY 2024 Q3$2,149M; +50.6% vs FY 2024 Q2
FY 2024 Q4$2,148M; 0.0% vs FY 2024 Q3
FY 2025 Q1$933M; −56.6% vs FY 2024 Q4
FY 2025 Q2$1,545M; +65.6% vs FY 2025 Q1
FY 2025 Q3$2,291M; +48.3% vs FY 2025 Q2
FY 2025 Q4$2,626M; +14.6% vs FY 2025 Q3
FY 2026 Q1$916M; −65.1% vs FY 2025 Q4
FY 2026 Q2$1,991M; +117.4% vs FY 2026 Q1

Net margin

%

7.37%
Abbott Laboratories Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q217.19%
FY 2009 Q319.07%
FY 2009 Q417.5%
FY 2010 Q113.03%
FY 2010 Q214.63%
FY 2010 Q310.27%
FY 2010 Q414.45%
FY 2011 Q19.55%
FY 2011 Q220.2%
FY 2011 Q33.09%
FY 2011 Q415.6%
FY 2012 Q113.13%
FY 2012 Q217.59%
FY 2012 Q319.88%
FY 2012 Q49.72%
FY 2013 Q110.13%
FY 2013 Q28.74%
FY 2013 Q317.99%
FY 2013 Q410.42%
FY 2014 Q17.15%
FY 2014 Q28.39%
FY 2014 Q310.54%
FY 2014 Q416.9%
FY 2015 Q146.8%
FY 2015 Q215.16%
FY 2015 Q311.26%
FY 2015 Q414.78%
FY 2016 Q16.47%
FY 2016 Q211.53%
FY 2016 Q3-6.21%
FY 2016 Q414.96%
FY 2017 Q16.61%
FY 2017 Q24.26%
FY 2017 Q38.83%
FY 2017 Q4-10.91%
FY 2018 Q15.66%
FY 2018 Q29.44%
FY 2018 Q37.35%
FY 2018 Q48.42%
FY 2019 Q18.92%
FY 2019 Q212.61%
FY 2019 Q311.89%
FY 2019 Q412.62%
FY 2020 Q17.3%
FY 2020 Q27.33%
FY 2020 Q313.92%
FY 2020 Q420.2%
FY 2021 Q117.15%
FY 2021 Q211.63%
FY 2021 Q319.22%
FY 2021 Q417.34%
FY 2022 Q120.57%
FY 2022 Q217.93%
FY 2022 Q313.78%
FY 2022 Q410.24%
FY 2023 Q113.52%
FY 2023 Q213.78%
FY 2023 Q314.16%
FY 2023 Q415.56%
FY 2024 Q112.29%
FY 2024 Q212.55%
FY 2024 Q315.48%
FY 2024 Q484.1%
FY 2025 Q112.79%
FY 2025 Q215.97%
FY 2025 Q314.46%
FY 2025 Q415.5%
FY 2026 Q19.65%
FY 2026 Q27.37%

P/E

× · TTM · Daily

32.69×
Abbott Laboratories P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-2918.88×2011-12-31
2012-03-3020.44×2011-12-31
2012-04-3020.7×2011-12-31
2012-05-3120.61×2011-12-31
2012-06-2921.5×2011-12-31
2012-07-3122.12×2011-12-31
2012-08-3121.86×2011-12-31
2012-09-2822.87×2011-12-31
2012-10-3121.85×2011-12-31
2012-11-3015.87×2012-09-30
2012-12-3116×2012-09-30
2013-01-3117.24×2012-09-30
2013-02-28-20.08×2012-12-31
2013-03-28-20.99×2012-12-31
2013-04-30-21.94×2012-12-31
2013-05-31-21.79×2012-12-31
2013-06-28-20.72×2012-12-31
2013-07-31-21.76×2012-12-31
2013-08-30-19.8×2012-12-31
2013-09-30-19.72×2012-12-31
2013-10-31-21.72×2012-12-31
2013-11-29-22.69×2012-12-31
2013-12-31-22.77×2012-12-31
2014-01-31-21.78×2012-12-31
2014-02-2824.36×2013-12-31
2014-03-3123.59×2013-12-31
2014-04-3023.73×2013-12-31
2014-05-3025.76×2014-03-31
2014-06-3026.33×2014-03-31
2014-07-3127.12×2014-03-31
2014-08-2926.8×2014-06-30
2014-09-3026.39×2014-06-30
2014-10-3127.66×2014-06-30
2014-11-2834.5×2014-09-30
2014-12-3134.89×2014-09-30
2015-01-3034.69×2014-09-30
2015-02-2736.71×2014-09-30
2015-03-3131.03×2014-12-31
2015-04-3031.09×2014-12-31
2015-05-2917.6×2015-03-31
2015-06-3017.77×2015-03-31
2015-07-3118.36×2015-03-31
2015-08-3116.4×2015-03-31
2015-09-3014.57×2015-03-31
2015-10-3016.22×2015-03-31
2015-11-3016.27×2015-03-31
2015-12-3116.26×2015-03-31
2016-01-2913.71×2015-03-31
2016-02-2913.17×2015-12-31
2016-03-3114.22×2015-12-31
2016-04-2913.22×2015-12-31
2016-05-3113.47×2015-12-31
2016-06-3013.36×2015-12-31
2016-07-2915.21×2015-12-31
2016-08-3114.28×2015-12-31
2016-09-3014.38×2015-12-31
2016-10-3113.34×2015-12-31
2016-11-3041.18×2016-09-30
2016-12-3041.54×2016-09-30
2017-01-3145.18×2016-09-30
2017-02-2848.02×2016-12-31
2017-03-3147.31×2016-12-31
2017-04-2846.49×2016-12-31
2017-05-3152.89×2017-03-31
2017-06-3056.31×2017-03-31
2017-07-3156.97×2017-03-31
2017-08-3176.34×2017-06-30
2017-09-2979.97×2017-06-30
2017-10-3181.27×2017-06-30
2017-11-3047.15×2017-09-30
2017-12-2947.74×2017-09-30
2018-01-3152×2017-09-30
2018-02-28226.54×2017-12-31
2018-03-29225×2017-12-31
2018-04-30218.28×2017-12-31
2018-05-31231.59×2018-03-31
2018-06-29229.56×2018-03-31
2018-07-31246.69×2018-03-31
2018-08-31128.8×2018-06-30
2018-09-28141.36×2018-06-30
2018-10-31132.84×2018-06-30
2018-11-30149.59×2018-09-30
2018-12-31146.12×2018-09-30
2019-01-31147.43×2018-09-30
2019-02-2858.51×2018-12-31
2019-03-2960.26×2018-12-31
2019-04-3059.98×2018-12-31
2019-05-3151.78×2019-03-31
2019-06-2857.2×2019-03-31
2019-07-3159.24×2019-03-31
2019-08-3052.74×2019-06-30
2019-09-3051.72×2019-06-30
2019-10-3151.68×2019-06-30
2019-11-2946.54×2019-09-30
2019-12-3147.31×2019-09-30
2020-01-3147.46×2019-09-30
2020-02-2837.43×2019-12-31
2020-03-3138.35×2019-12-31
2020-04-3046.01×2020-03-31
2020-05-2947.42×2020-03-31
2020-06-3045.68×2020-03-31
2020-07-3157.99×2020-06-30
2020-08-3163.08×2020-06-30
2020-09-3062.71×2020-06-30
2020-10-3060.56×2020-06-30
2020-11-3057.41×2020-09-30
2020-12-3158.09×2020-09-30
2021-01-2965.57×2020-09-30
2021-02-2647.94×2020-12-31
2021-03-3147.97×2020-12-31
2021-04-3048.06×2020-12-31
2021-05-2836.69×2021-03-31
2021-06-3036.46×2021-03-31
2021-07-3038.05×2021-03-31
2021-08-3139.75×2021-03-31
2021-09-3037.15×2021-03-31
2021-10-2940.54×2021-03-31
2021-11-3039.56×2021-03-31
2021-12-3144.27×2021-03-31
2022-01-3140.09×2021-03-31
2022-02-2830.53×2021-12-31
2022-03-3129.96×2021-12-31
2022-04-2928.73×2021-12-31
2022-05-3129.73×2021-12-31
2022-06-3027.5×2021-12-31
2022-07-2927.55×2021-12-31
2022-08-3125.98×2021-12-31
2022-09-3024.49×2021-12-31
2022-10-3125.04×2021-12-31
2022-11-3024.15×2022-09-30
2022-12-3024.64×2022-09-30
2023-01-3124.82×2022-09-30
2023-02-2825.82×2022-12-31
2023-03-3125.7×2022-12-31
2023-04-2828.04×2022-12-31
2023-05-3130.91×2023-03-31
2023-06-3033.04×2023-03-31
2023-07-3133.74×2023-03-31
2023-08-3135.03×2023-06-30
2023-09-2932.97×2023-06-30
2023-10-3132.19×2023-06-30
2023-11-3035.45×2023-09-30
2023-12-2937.42×2023-09-30
2024-01-3138.46×2023-09-30
2024-02-2936.33×2023-12-31
2024-03-2834.81×2023-12-31
2024-04-3032.45×2023-12-31
2024-05-3131.88×2024-03-31
2024-06-2832.41×2024-03-31
2024-07-3133.05×2024-03-31
2024-08-3035.33×2024-03-31
2024-09-3035.56×2024-03-31
2024-10-3135.36×2024-03-31
2024-11-2937.05×2024-03-31
2024-12-3135.28×2024-03-31
2025-01-3139.91×2024-03-31
2025-02-2818.03×2024-12-31
2025-03-3117.32×2024-12-31
2025-04-3017.08×2024-12-31
2025-05-3017.45×2024-12-31
2025-06-3017.76×2024-12-31
2025-07-3116.48×2024-12-31
2025-08-2917.33×2024-12-31
2025-09-3017.49×2024-12-31
2025-10-3115.56×2025-09-30
2025-11-2816.23×2025-09-30
2025-12-3115.77×2025-09-30
2026-01-3013.76×2025-09-30
2026-02-2731.23×2025-12-31
2026-03-3127.56×2025-12-31
2026-04-3025.18×2026-03-31
2026-05-2923.74×2026-03-31
2026-06-3025.16×2026-03-31
2026-07-3134.12×2026-06-30
2026-08-3135.62×2026-06-30
2026-09-2532.69×2026-06-30
Mean 39.81×Median 32.42×1% above median

ROIC

% · Annual / TTM

7.77%
Abbott Laboratories ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q414.44%
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q414.76%
FY 2012 Q113.88%
FY 2012 Q213.66%
FY 2012 Q319.21%
FY 2012 Q422.11%
FY 2013 Q122.36%
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q47.67%
FY 2014 Q18.23%
FY 2014 Q28.51%
FY 2014 Q36.64%
FY 2014 Q46.61%
FY 2015 Q17.3%
FY 2015 Q27.91%
FY 2015 Q38.58%
FY 2015 Q49.25%
FY 2016 Q18.72%
FY 2016 Q28.98%
FY 2016 Q38.31%
FY 2016 Q49.7%
FY 2017 Q14.38%
FY 2017 Q23.48%
FY 2017 Q34.3%
FY 2017 Q40.74%
FY 2018 Q11.03%
FY 2018 Q22.17%
FY 2018 Q32.24%
FY 2018 Q46.17%
FY 2019 Q16.6%
FY 2019 Q27.23%
FY 2019 Q37.97%
FY 2019 Q48.91%
FY 2020 Q18.59%
FY 2020 Q27.57%
FY 2020 Q38.19%
FY 2020 Q410.66%
FY 2021 Q113.44%
FY 2021 Q214.68%
FY 2021 Q316.6%
FY 2021 Q416.27%
FY 2022 Q117.67%
FY 2022 Q219.67%
FY 2022 Q318.49%
FY 2022 Q415.85%
FY 2023 Q112.83%
FY 2023 Q211.08%
FY 2023 Q311.22%
FY 2023 Q412.31%
FY 2024 Q111.86%
FY 2024 Q211.81%
FY 2024 Q312.12%
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q411.12%
FY 2026 Q18.76%
FY 2026 Q27.77%

Capital allocation

% of tracked cash uses

$4,049M
Abbott Laboratories capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q218.77% · $262.74M1.24% · $17.332M0.13% · $1.828M44.16% · $618.227M35.71% · $500M100% · $1,400.127M
FY 2009 Q334.34% · $328.71M0.99% · $9.512M0.06% · $0.605M64.6% · $618.376M0% · $0M100% · $957.203M
FY 2009 Q414.3% · $245.447M49.61% · $851.727M0.06% · $0.959M36.04% · $618.776M0% · $0M100% · $1,716.909M
FY 2010 Q13.01% · $245.143M78.78% · $6,415.648M10.58% · $861.368M7.62% · $620.752M0.02% · $1.254M100% · $8,144.165M
FY 2010 Q218.74% · $273.514M34.56% · $504.395M0.17% · $2.479M46.53% · $679.199M0% · $0M100% · $1,459.587M
FY 2010 Q36.64% · $205.085M71.27% · $2,200M0.08% · $2.326M22.01% · $679.423M0% · $0M100% · $3,086.834M
FY 2010 Q49.81% · $291.333M10.55% · $313.2M0.02% · $0.652M23.3% · $692.101M56.32% · $1,672.744M100% · $2,970.03M
FY 2011 Q123.77% · $391.813MUnavailable4.35% · $71.75M41.5% · $683.967M30.37% · $500.582M100% · $1,648.112M
FY 2011 Q214.17% · $372.957MUnavailable0.08% · $2.095M28.52% · $750.409M57.23% · $1,506.097M100% · $2,631.558M
FY 2011 Q326.72% · $451.995M28.68% · $485M0.03% · $0.583M44.44% · $751.63M0.13% · $2.157M100% · $1,691.365M
FY 2011 Q413.51% · $274.735M0% · $0M0.13% · $2.579M36.99% · $752.09M49.37% · $1,003.59M100% · $2,032.994M
FY 2012 Q115.5% · $453.33M22.94% · $670.849M33.77% · $987.686M25.94% · $758.548M1.85% · $54M100% · $2,924.413M
FY 2012 Q220.47% · $425.116M5.3% · $110M35.37% · $734.428M38.86% · $806.984M0% · $0M100% · $2,076.528M
FY 2012 Q330.17% · $530.747M23.97% · $421.624M0.07% · $1.234M45.79% · $805.405M0% · $0M100% · $1,759.01M
FY 2012 Q43% · $386.096M0.19% · $25M4.98% · $640.892M6.3% · $811.874M85.53% · $11,017.178M100% · $12,881.04M
FY 2013 Q119.28% · $274.465MUnavailable65.01% · $925.333M15.71% · $223.561MUnavailable100% · $1,423.359M
FY 2013 Q236.27% · $290.419MUnavailable36.19% · $289.818M27.54% · $220.536MUnavailable100% · $800.773M
FY 2013 Q332.63% · $276.457MUnavailable41.43% · $351.008M25.93% · $219.687MUnavailable100% · $847.152M
FY 2013 Q452.86% · $303.659M2.39% · $13.729M6.76% · $38.841M37.99% · $218.216MUnavailable100% · $574.445M
FY 2014 Q19.14% · $255MUnavailable78.57% · $2,192M12.29% · $343MUnavailable100% · $2,790M
FY 2014 Q243.58% · $258MUnavailable0.17% · $1M56.25% · $333MUnavailable100% · $592M
FY 2014 Q345.48% · $277MUnavailable0.16% · $1M54.35% · $331MUnavailable100% · $609M
FY 2014 Q425.67% · $287M44.28% · $495M0.09% · $1M29.96% · $335MUnavailable100% · $1,118M
FY 2015 Q112.02% · $235MUnavailable68.85% · $1,346M18.62% · $364M0.51% · $10M100% · $1,955M
FY 2015 Q236% · $216MUnavailable0.17% · $1M60% · $360M3.83% · $23M100% · $600M
FY 2015 Q340.85% · $411M22.96% · $231M0.2% · $2M35.69% · $359M0.3% · $3M100% · $1,006M
FY 2015 Q416.35% · $248M0% · $0M58.54% · $888M23.73% · $360M1.38% · $21M100% · $1,517M
FY 2016 Q121.06% · $243MUnavailable44.97% · $519M33.36% · $385M0.61% · $7M100% · $1,154M
FY 2016 Q238.9% · $247MUnavailable0.16% · $1M60.47% · $384M0.47% · $3M100% · $635M
FY 2016 Q340.78% · $312M8.63% · $66M0.26% · $2M50.2% · $384M0.13% · $1M100% · $765M
FY 2016 Q444.74% · $319M0.98% · $7M0% · $0M54.14% · $386M0.14% · $1M100% · $713M
FY 2017 Q11.66% · $272M79.63% · $13,027M0.58% · $95M2.81% · $460M15.31% · $2,505M100% · $16,359M
FY 2017 Q235.32% · $255M0% · $0M0.42% · $3M63.99% · $462M0.28% · $2M100% · $722M
FY 2017 Q335.78% · $263M0% · $0M1.09% · $8M62.99% · $463M0.14% · $1M100% · $735M
FY 2017 Q43.1% · $345M37.38% · $4,156M0.1% · $11M4.17% · $464M55.24% · $6,142M100% · $11,118M
FY 2018 Q13.99% · $275M0.36% · $25M1.86% · $128M7.12% · $491M86.68% · $5,979M100% · $6,898M
FY 2018 Q214.1% · $298M0.85% · $18M0.14% · $3M23.37% · $494M61.54% · $1,301M100% · $2,114M
FY 2018 Q319.14% · $354MUnavailable0.16% · $3M26.7% · $494M54% · $999M100% · $1,850M
FY 2018 Q48.95% · $467MUnavailable1.99% · $104M9.48% · $495M79.58% · $4,154M100% · $5,220M
FY 2019 Q119.76% · $335M4.6% · $78M12.8% · $217M33.33% · $565M29.5% · $500M100% · $1,695M
FY 2019 Q240.94% · $468M7.17% · $82M0.35% · $4M49.69% · $568M1.84% · $21M100% · $1,143M
FY 2019 Q341.21% · $401MUnavailable0.1% · $1M58.48% · $569M0.21% · $2M100% · $973M
FY 2019 Q49.83% · $434MUnavailable11.23% · $496M12.86% · $568M66.08% · $2,918M100% · $4,416M
FY 2020 Q129.15% · $360MUnavailable19.11% · $236M51.66% · $638M0.08% · $1M100% · $1,235M
FY 2020 Q249.81% · $642MUnavailable0.31% · $4M49.81% · $642M0.08% · $1M100% · $1,289M
FY 2020 Q320.11% · $496MUnavailable0.08% · $2M25.9% · $639M53.91% · $1,330M100% · $2,467M
FY 2020 Q445.82% · $679MUnavailable10.86% · $161M43.25% · $641M0.07% · $1M100% · $1,482M
FY 2021 Q126.93% · $397MUnavailable18.66% · $275M54.27% · $800M0.14% · $2M100% · $1,474M
FY 2021 Q224.44% · $413MUnavailable27.87% · $471M47.51% · $803M0.18% · $3M100% · $1,690M
FY 2021 Q324.51% · $461MUnavailable30.78% · $579M42.58% · $801M2.13% · $40M100% · $1,881M
FY 2021 Q425.7% · $614MUnavailable40.77% · $974M33.4% · $798M0.13% · $3M100% · $2,389M
FY 2022 Q17.62% · $321MUnavailable54.79% · $2,307M19.76% · $832M17.83% · $751M100% · $4,211M
FY 2022 Q231.24% · $379MUnavailable0.41% · $5M68.26% · $828M0.08% · $1M100% · $1,213M
FY 2022 Q322.32% · $467MUnavailable38.15% · $798M39.48% · $826M0.05% · $1M100% · $2,092M
FY 2022 Q428.8% · $610MUnavailable32.34% · $685M38.86% · $823MUnavailable100% · $2,118M
FY 2023 Q120.99% · $380MUnavailable29.83% · $540M49.17% · $890M0% · $0M100% · $1,810M
FY 2023 Q227.78% · $507MUnavailable23.34% · $426M48.77% · $890M0.11% · $2M100% · $1,825M
FY 2023 Q319.34% · $560MUnavailable0.07% · $2M30.67% · $888M49.91% · $1,445M100% · $2,895M
FY 2023 Q439.7% · $755MUnavailable13.62% · $259M46.69% · $888MUnavailable100% · $1,902M
FY 2024 Q125.17% · $398MUnavailable14.29% · $226M60.53% · $957M0% · $0M100% · $1,581M
FY 2024 Q235.18% · $533MUnavailable0.2% · $3M63.43% · $961M1.19% · $18M100% · $1,515M
FY 2024 Q324.5% · $556MUnavailable33.1% · $751M42.31% · $960M0.09% · $2M100% · $2,269M
FY 2024 Q436.13% · $720MUnavailable15.81% · $315M48.07% · $958MUnavailable100% · $1,993M
FY 2025 Q117.34% · $484MUnavailable10.03% · $280M36.76% · $1,026M35.87% · $1,001M100% · $2,791M
FY 2025 Q232.64% · $502MUnavailable0.39% · $6M66.91% · $1,029M0.07% · $1M100% · $1,538M
FY 2025 Q321.26% · $496MUnavailable13.07% · $305M44.19% · $1,031M21.47% · $501M100% · $2,333M
FY 2025 Q434.09% · $689MUnavailable14.94% · $302M50.96% · $1,030MUnavailable100% · $2,021M
FY 2026 Q112.9% · $399MUnavailable5.82% · $180M35.5% · $1,098M45.78% · $1,416M100% · $3,093M
FY 2026 Q212.27% · $497MUnavailable25.81% · $1,045M27.22% · $1,102M34.7% · $1,405M100% · $4,049M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Abbott Laboratories.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources